Company News

Our products’ environmental performance is a core pillar of our commitment to protecting the planet. For several years, bioMérieux has been implementing a continuous improvement approach based on Life Cycle Assessments (LCAs) of our diagnostic solutions. The goal is to measure our products’ impact on the climate and environment across the entire value chain — from manufacturing and customer use to end-of-life management.

In line with our public health mission, bioMérieux and BioFire Defense, a bioMérieux company, are mobilizing Ebola diagnostics to support ongoing efforts related to the current Ebola outbreak in Africa.

Preserving the planet to protect health: our commitments and progress

Fully aware of today’s climate and environmental challenges, we are taking action to reduce the footprint of our activities, optimize the use of resources, and design increasingly responsible solutions. Since 2019, we have been committed to an ambitious environmental trajectory. Here is an overview of the concrete, measurable, and sustainable actions implemented by our teams around the world.

In the ICU, minutes count — particularly for patients with sepsis, where a sudden drop in blood pressure can signal a dangerous turn. If care teams can see that change coming, even by a couple of hours, they can prepare, personalize treatment, and potentially prevent a crisis. That’s where interpretable, clinically grounded AI can help — turning routine hospital data into early warning signs.

bioMérieux announces an investment of more than one million Swiss Francs in Plair, a scale-up company offering a breakthrough solution for real-time microbial detection and air sampling.